Abstract
The currently available vaccines against influenza are viral strain specific and, hence, their efficacy is limited when the circulating strain is not the one included in them. We review herewith some of the more recently developed influenza vaccines and further describe our own data on the design of epitope-based broad-spectrum vaccine for human use. This vaccine is comprised of recombinant flagella that act as a carrier and adjuvant, expressing conserved epitopes of influenza proteins. These epitopes are common to the vast majority of influenza virus strains regardless of their antigenic drifts and shifts. The vaccine, activating both the humoral and cellular arms of the immune response, induces long-lasting protection against many strains of the influenza virus. Consequently, it is expected to protect against future strains as well.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
